Margarita Sordo
ABSTRACT
We propose and evaluate the use of a Particle Swarm Optimization/Ant Colony Optimization (PSO/ACO) methodology for classification and rule discovery in the context of medication postmarketing surveillance or pharmacovigilance. Our study considers a large data set of diabetic patients on two widely used antidiabetic drugs (rosiglitazone and pioglitazone), and the risk of myocardial infarction as an adverse effect. The goal is to determine the presence of previously undetected causal relationships between therapeutics, patient characteristics, and adverse medication outcomes. Since the proposed approach is able to discover classification rules, the elicited knowledge may suggest new hypotheses regarding associations between risk factors and an adverse event. Our classification results show high accuracy. Furthermore, several medication-related rules were discovered and analyzed. The elicited rules support previous studies from the medical literature. Moreover, one of the studied antidiabetic drugs (rosiglitazone) was found to have a significant higher risk of an adverse event on diabetic, hypertensive patients, as compared to the other drug. This last finding suggests that pioglitazone may have a protective effect against myocardial infarction on diabetic, hypertensive patients.
- Beddhu S., Allen-Brady K., Cheung A.K., Horne B.D., Bair T., Muhlestein J.B. and Anderson J.L. Impact of renal failure on the risk of myocardial infarction and death. Kidney International (2002) 62, 1776--1783.Google Scholar
- Booth G.L., Kapral M.K., Fung K.T., Jack V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. The Lancet 2006; 368(9529):29--36.Google Scholar
- Brownstein J.S., Murphy S.N., Goldfine A.B., Grant R.W., Sordo M., Gainer V., Colecchi J., Dubey A., Nathan D.M., Glaser J.P., Kohane I.S. Real-time surveillance of cardiovascular risk associated with diabetic medications from electronic medical records.Tech Report 2009Google Scholar
- Brownstein J.S., Sordo M., Kohane I.S., Mandl K.D. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2007;2(9):e840.Google Scholar
- Caldwell B., Aldington S., Weatherall M., Shirtcliffe P., Beasley R. (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 99: 132--140.Google ScholarCross Ref
- Canto J.G., Shlipak M.G., Rogers W.J., Malmgren J.A., Frederick P.D., Lambrew C.T., Ornato J.P., Barron H.V., Kiefe C.I. (2000). Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA. 2000;283(24): 3223--9.Google Scholar
- Carvalho D.R., Freitas A.A., Ebecken N. Evaluating the Correlation Between Objective Rule Interestingness Measures and Real Human Interest. PKDD 2005, LNAI 3721, pp 453--461. Google ScholarDigital Library
- Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279--89.Google Scholar
- FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. FDA News. 2004 Sep 30. http://www.fda.gov/bbs/topics/news/2004/new01122.htmlGoogle Scholar
- Gerrits C.M., Bhattacharya M., Manthena S., Baran R., Perez A., Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16(10):1065--71.Google Scholar
- Graham D.J., Campen D., Hui R., Spence M., Cheetham C., et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo--oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475--481.Google ScholarCross Ref
- Greenes R.A., Sordo M., Zaccagnini D., Meyer M., Kuperman G.J. Design of a Standards-Based External Rules Engine for Decision Support in a Variety of Application Contexts: Report of a Feasibility Study at Partners HealthCare System. Proceedings of Medical Informatics Association (MedInfo), September, 2004.Google Scholar
- Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229--34.Google Scholar
- He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in U.S. men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161: 996--1002.Google Scholar
- Hennekens C.H., Buring J. Epidemiology in Medicine. Little Brown and Co. 1987.Google Scholar
- Hippisley-Cox J., Coupland C. (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366.Google ScholarCross Ref
- Holden N., Freitas A.A. A Hybrid PSO/ACO algorithm for classification. Proceedings of the 9th Genetic and Evolutionary Computation Conference Workshop on Particle Swarms: The Second Decade (GECCO '07), pp. 2745--2750, ACM Press, London, UK, July 2007. Google ScholarDigital Library
- Holden N., Freitas A.A. A Hybrid PSO/ACO Algorithm for Discovering Classification Rules in Data Mining. Journal of Artificial evolution and Applications. Vol 2008, Article id 316145, 11 pages. Google ScholarCross Ref
- Holden N., Freitas A.A. PSO/ACO2 Java application. Downloads at http://sourceforge.net/projects/psoaco2/Google Scholar
- Institute of Medicine, The Future of Drug Safety- Promoting and Protecting the Health of the Public, September 22, 2006, http://www.iom.edu/.Google Scholar
- S.B. King III. Acute myocardial infarction: are diabetics different? J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1513--1515.Google Scholar
- Nesto R., Libby P. Diabetes mellitus and the cardiovascular system. In: Braunwald E., Zipes D.P., Libby P., eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, Pa: W.B. Saunders Co; 2001: 2133--2150.Google Scholar
- Nichols G.A., Hillier T.A., Erbey J.R., et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001; 24: 1614--1619.Google Scholar
- Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes {published correction appears N Engl J Med. 2007;357(1): 100}. N Engl J Med 2007;356(24):2457--2471.Google Scholar
- Qaseem A., Vijan S., Snow V., Cross T., Weiss K.B., Owens D.K. Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1C Targets. A Guidance Statement from the American College of Physicians. Ann Inter Med 2007; 147: 417--422.Google Scholar
- Singer D.E., Nathan D.M., Anderson K.M., Wilson P.W., Evans J.C. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes, Vol 41, Issue 2 202--208.Google Scholar
- Singh S., Loke Y.K., Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189--1195.Google Scholar
- Solomon D.H., Schneeweiss S., Glynn R.J., Kiyota Y., Levin R., et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068--2073.Google ScholarCross Ref
- Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071--1080.Google ScholarCross Ref
- Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351(11):1106--1118.Google Scholar
- Winkelmayer W.C., Setoguchi S., Levin R., Solomon D.H. Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy. Arch Intern Med 2008;168(21):2368--75.Google Scholar
Index Terms
- A PSO/ACO approach to knowledge discovery in a pharmacovigilance context
Recommendations
Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data
KDD '17: Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data MiningSeveral prominent public health incidents that occurred at the beginning of this century due to adverse drug events (ADEs) have raised international awareness of governments and industries about pharmacovigilance (PhV), the science and activities to ...
Data mining methodologies for pharmacovigilance
Medicines are designed to cure, treat, or prevent diseases; however, there are also risks in taking any medicine - particularly short term or long term adverse drug reactions (ADRs) can cause serious harm to patients. Adverse drug events have been ...
Users' Perception towards the "Safe Medication through Pharmacovigilance and Compliance Monitoring Pharmacov" Service
A feasibility study was conducted to evaluate the acceptability and effectiveness of the "Safe medication through pharmacovigilance and compliance monitoring PharmacoV" service, an Internet-based interactive information tool that assists physicians in ...
Comments